#Olverembatinib, a novel #MultiKinaseInhibitor, demonstrates strong efficacy and safety in SDH-deficient GISTs resistant to #TKIs, mechanistically suppressing #LipidUptake and #CD36-associated tumorigenic pathways. #GISTs #CD36

#OpenAccess in #STTT: doi.org/10.1038/s413...